TYME - Tyme Technologies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.4800
+0.0600 (+4.23%)
As of 3:34PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.4200
Open1.4200
Bid1.4700 x 800
Ask1.4800 x 900
Day's Range1.3797 - 1.4800
52 Week Range0.9200 - 4.6420
Volume396,734
Avg. Volume450,240
Market Cap165.687M
Beta (3Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)-0.2800
Earnings DateNov 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Trade prices are not sourced from all markets
  • GlobeNewswire

    TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results

    TYME Launched the Pivotal Stage of TYME-88-PANC Trial to Evaluate Oral SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic CancerTYME Presented Final Data at.

  • Lilly's Pancreatic Cancer Candidate Fails in Phase III Study
    Zacks

    Lilly's Pancreatic Cancer Candidate Fails in Phase III Study

    Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.

  • How Much Are Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Taking Off The Table?
    Simply Wall St.

    How Much Are Tyme Technologies, Inc. (NASDAQ:TYME) Insiders Taking Off The Table?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • GlobeNewswire

    TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer

    Study results demonstrate that oral SM-88 may play a clinically meaningful role in postponing use of hormonal castration in prostate cancer patients with rising.

  • GlobeNewswire

    TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging overall (OS) results and has a well-tolerated safety profile. TYME also announced encouraging Quality of Life data for this challenging patient population.

  • Tyme Initiates Pivotal Stage of Pancreatic Cancer Study
    Zacks

    Tyme Initiates Pivotal Stage of Pancreatic Cancer Study

    Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.

  • GlobeNewswire

    TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the start of the pivotal stage of the TYME-88-Panc trial to evaluate the clinical benefits of its lead CMBT candidate, oral SM-88 (racemetyrosine), for third-line treatment of patients with metastatic pancreatic cancer. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death.

  • GlobeNewswire

    Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019. The Company will present its corporate overview for 2019 with a special focus on growth opportunities driven by advancements in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate, and sarcoma cancers. A live webcast of the presentation will be accessible on the events page under the Investor Relations section of Tyme Technologies’ website at www.tymeinc.com.

  • Will Tyme Technologies Continue to Surge Higher?
    Zacks

    Will Tyme Technologies Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor Tyme Technologies.

  • GlobeNewswire

    TYME Presents Positive Circulating Tumor Cell Data from TYME-88-Panc Study in Patients with Advanced Pancreatic Cancer at AACR PANC 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), reported encouraging data on circulating tumor cells (CTCs) and a correlation with decrease in risk of death using TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer. The data were presented at the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, taking place September 6-9, 2019, at the Westin Copley Place in Boston, Massachusetts.

  • GlobeNewswire

    Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright in New York City on Monday, September 9, 2019. The Company will present its corporate overview for 2019 with special focus on growth opportunities driven by advances in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers.

  • GlobeNewswire

    TYME Announces Abstracts Selected for Presentation at the European Society of Medical Oncology Congress 2019

    SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancersNew oral approach aimed at.

  • GlobeNewswire

    Tyme Technologies to Present at BTIG Biotechnology Conference on August 12th, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the BTIG Biotechnology Conference in New York on August 12th, 2019. In one-on-one sessions, the Company will present its corporate overview for 2019 with special focus on growth opportunities driven by advances in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers.

  • GlobeNewswire

    TYME Provides Business Update and Reports First Quarter Fiscal 2020 Financial and Operating Results

    TYME Presented Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic CancerNYU.

  • GlobeNewswire

    TYME Announces Abstracts Selected for Presentation at the AACR Special Conference on Pancreatic Cancer

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that two abstracts highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer have been selected for poster presentation at the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, taking place September 6-9, 2019, at the Westin Copley Place in Boston, Massachusetts. Additional information on the meeting can be found on the AACR Special Conference on Pancreatic Cancer website: https://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=180.

  • GlobeNewswire

    Tyme Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference on August 7th, 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 39th Annual Canaccord Genuity Growth Conference in Boston on August 7th, 2019. The Company will present its corporate overview for 2019 with special focus on growth opportunities driven by advances in the science of cancer metabolism and clinical developments for its lead candidate SM-88 (racemetyrosine) in pancreatic, prostate and sarcoma cancers.

  • GlobeNewswire

    TYME Technologies Announces New Collaboration with NYU Langone to Advance TYME’s Cancer Metabolism-Based Therapy, SM-88

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company, announced a new research collaboration with NYU Langone Health to advance the development of innovative treatments for patients with metastatic cancers, including pancreatic cancer. The collaboration will leverage NYU Langone’s state-of-the-art technologies to help inform the development of clinical therapies, focusing on identifying potential future biomarkers or combination approaches to treat cancer. “We are excited to collaborate on this new effort to help uncover key findings about how specific biomarkers may help slow the development of certain cancer types,” said Diane Simeone, MD, Director of the Pancreatic Cancer Center at NYU Langone Health’s Perlmutter Cancer Center and Lead Principle Investigator for the Pancreatic Cancer Network’s Precision PromiseSM trials.

  • GlobeNewswire

    REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

    TYME management will be hosting a conference call on July 9th at 8:30AM EDT to discuss the SM-88 data presented at the ESMO GI Congress. NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging results and a well-tolerated safety profile.

  • Tyme Technologies News: Why TYME Stock Is Rocketing
    InvestorPlace

    Tyme Technologies News: Why TYME Stock Is Rocketing

    Tyme Technologies (NASDAQ:TYME) stock is skyrocketing on Friday following the company's announcement regarding the latest data from one of its cancer treatments.Source: Shutterstock The U.S. biotechnology company revealed that it had amassed positive updated data regarding its phase 2 study of SM-88, which is a treatment designed to help out patients with pancreatic cancer. This led to trading volume increasing to more than 4.1 million shares, which is more than six times the full-day average.Tyme Technologies said before the open that data from the study of SM-88 as an oral monotherapy revealed that the median overall survival of patients was 6.4 months, which compares favorably next to historical trials that showed survival of 2.0 to 2.5 months. "We believe that these outcomes further justify advancing the development of SM-88," said Chief Medical Officer Giuseppe Del Priore.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"We are increasingly encouraged that SM-88 has the potential to be a new treatment approach for late-stage pancreatic patients," he added.TYME stock is soaring about 22.5% on Friday afternoon following the news, which brought the price of the stock up to $1.50 per share. The stock had closed at around $1.22 per share by day's end on Wednesday, which is the price it opened at today-the stock market was not open yesterday in observation of Independence Day.The stock is still down more than 50% year-to-date, although the boost helped it move in the right direction. More From InvestorPlace * The Top 8 Tech Stocks of 2019 (So Far) * The 7 Top Small-Cap Stocks Of 2019 * 7 F-Rated Stocks to Sell for Summer * 7 Retail Stocks to Buy That Are Down in 2019 The post Tyme Technologies News: Why TYME Stock Is Rocketing appeared first on InvestorPlace.

  • GlobeNewswire

    TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

    Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in patients with advanced pancreatic cancer continues to demonstrate encouraging results and a well-tolerated safety profile. The data from the TYME-88-Panc study were presented at the European Society of Medical Oncology 21st World Congress on Gastrointestinal Cancer (ESMO GI) on July 4, 2019 in Barcelona, Spain.

  • Will Tyme Technologies, Inc.'s (NASDAQ:TYME) Earnings Grow Over The Next Few Years?
    Simply Wall St.

    Will Tyme Technologies, Inc.'s (NASDAQ:TYME) Earnings Grow Over The Next Few Years?

    In June 2019, Tyme Technologies, Inc. (NASDAQ:TYME) released its most recent earnings announcement, which revealed...

  • GuruFocus.com

    Weekly CFO Buys Highlight

    Recent buys from company CFOs

  • GlobeNewswire

    TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019

    Tyme Technologies, Inc. (TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an abstract highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer has been selected for poster presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer (ESMO GI) being held on July 3-6, 2019 in Barcelona, Spain. Additional information on the meeting can be found on the ESMO World Congress on Gastrointestinal Cancer website: https://www.worldgicancer.com.

  • GlobeNewswire

    TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results

    TYME-88-Panc Continues to Show Encouraging Survival Trend with Additional Data to Be Presented in Third Quarter 2019Single Agent SM-88 (racemetyrosine) Shown to Have Anti-Tumor.